Mirabegron

Generic name: Pronounced as (mir'' a beg' ron)
Brand names
  • Myrbetriq®
Click on drug name to hear pronunciation

Medical Content Reviewed By HelloPharmacist Staff

Last Revised - 06/15/2021

Mirabegron is used alone or in combination with solifenacin (Vesicare) to treat overactive bladder (a condition in which the bladder muscles contract uncontrollably and cause frequent urination, urgent need to urinate, and inability to control urination) in adults. It is also used to treat neurogenic detrusor overactivity (a bladder control condition caused by brain, spinal cord or nerve problem) in children 3 years of age and older. Mirabegron is in a class of medications called beta-3 adrenergic agonists. It works by relaxing the bladder muscles to prevent urgent, frequent, or uncontrolled urination.

Mirabegron comes as an extended-release (long-acting) tablet and as an extended-release suspension to take by mouth. The tablets are usually taken with or without food once a day in adults and with food once a day in children. The suspension is usually taken with food once a day. Take mirabegron at around the same time every day. Follow the directions on your prescription label carefully, and ask your doctor or pharmacist to explain any part you do not understand. Take mirabegron exactly as directed. Do not take more or less of it or take it more often than prescribed by your doctor.

Swallow the extend-release tablets whole with water; do not split, chew, or crush them.

It is important to use the oral dosing device to accurately measure and take your dose of the extended-release suspension. Ask your pharmacist for a device if it was not provided. Shake the bottle vigorously for 1 minute, then let it stand for 1 to 2 minutes until the foam on top of the suspension is gone. If the granules have not mixed well, shake the bottle vigorously again for 1 minute and let it stand until the foam is gone. Use the oral dosing device to draw up the suspension and ignore any bubbles in your measurement. Do not save the dose in the dosing syringe for later; use within 1 hour after preparation. After each use, wash the oral dosing device with mild soap, then rinse with tap water and allow it to air dry. If the suspension is not used for 2 or more days, shake the bottle for 1 minute each day.

Your doctor may increase your dose, depending on how well your symptoms are controlled and the side effects you experience. Talk to your doctor about how you are feeling during your treatment with mirabegron.

Mirabegron controls the symptoms of overactive bladder or neurogenic detrusor overactivity, but does not cure these conditions. It may take 8 weeks or longer before you feel the full benefit of mirabegron. Continue to take mirabegron even if you feel well. Do not stop taking mirabegron without talking to your doctor.

Ask your pharmacist or doctor for a copy of the manufacturer's information for the patient.

This medication may be prescribed for other uses; ask your doctor or pharmacist for more information.

Before taking mirabegron,

  • tell your doctor and pharmacist if you are allergic to mirabegron, any other medications, or any of the ingredients in mirabegron extended-release tablets and suspension. Ask your pharmacist or check the patient information for a list of the ingredients.

  • tell your doctor and pharmacist what prescription and nonprescription medications, vitamins, nutritional supplements, and herbal products you are taking or plan to take. Be sure to mention any of the following: anticoagulants ('blood thinners) such as warfarin (Coumadin, Jantoven); desipramine (Norpramin); digoxin (Lanoxin); flecainide (Tambocor); other medications for overactive bladder such as darifenacin (Enablex), fesoterodine (Toviaz), oxybutynin ( Glenique, Oxytrol), solifenacin (VESIcare), tolterodine (Detrol), and trospium; propafenone (Rhythmol); metoprolol (Lopressor, Toprol, in Dutoprol); and thioridazine. Your doctor may need to change the doses of your medications or monitor you carefully for side effects.

  • tell your doctor if you have or have ever had bladder outlet obstruction (a blockage at the base of the bladder that stops urine from flowing freely out of the bladder and causes difficulty emptying the bladder and/or a weak urine stream), high blood pressure, or kidney or liver disease.

  • tell your doctor if you are pregnant, plan to become pregnant, or are breastfeeding. If you become pregnant while taking mirabegron, call your doctor.

  • you should know that your blood pressure may increase during your treatment with mirabegron. Your doctor will check your blood pressure regularly during your treatment.

Unless your doctor tells you otherwise, continue your normal diet.

If it has been less than 12 hours since the missed dose, take it as soon as you remember it. If it has been more than 12 hours since the missed dose, skip it and continue your regular dosing schedule. Do not take a double dose to make up for a missed one.

  • Mirabegron may cause side effects. Tell your doctor if any of these symptoms are severe or do not go away:

    • headache

    • dizziness

    • dry mouth

    • constipation

    • back pain

    • joint pain

    • difficulty emptying the bladder, or weak urine stream (especially when used with solifenacin)

  • Some side effects can be serious. If you experience any of these symptoms, call your doctor immediately or get emergency medical treatment:

    • swelling of face, lips, tongue or throat, difficulty breathing or swallowing, hives, rash, itching

    • difficult, painful, urgent, or frequent urination

  • Mirabegron may cause other side effects. Call your doctor if you have any unusual problems while taking this medication.

  • If you experience a serious side effect, you or your doctor may send a report to the Food and Drug Administration's (FDA) MedWatch Adverse Event Reporting program online (http://www.fda.gov/Safety/MedWatch) or by phone (1-800-332-1088).

Keep this medication in the container it came in, tightly closed, and out of reach of children. Store the tablets at room temperature and away from excess heat and moisture (not in the bathroom). Store the suspension at room temperature for up to 28 days after the date the pharmacist prepares the suspension.

It is important to keep all medication out of sight and reach of children as many containers (such as weekly pill minders and those for eye drops, creams, patches, and inhalers) are not child-resistant and young children can open them easily. To protect young children from poisoning, always lock safety caps and immediately place the medication in a safe location – one that is up and away and out of their sight and reach. http://www.upandaway.org

Unneeded medications should be disposed of in special ways to ensure that pets, children, and other people cannot consume them. However, you should not flush this medication down the toilet. Instead, the best way to dispose of your medication is through a medicine take-back program. Talk to your pharmacist or contact your local garbage/recycling department to learn about take-back programs in your community. See the FDA's Safe Disposal of Medicines website (http://goo.gl/c4Rm4p) for more information if you do not have access to a take-back program.

In case of overdose, call the poison control helpline at 1-800-222-1222. Information is also available online at https://www.poisonhelp.org/help. If the victim has collapsed, had a seizure, has trouble breathing, or can't be awakened, immediately call emergency services at 911.

Symptoms of overdose may include the following:

  • fast or pounding heartbeat

Keep all appointments with your doctor.

Do not let anyone else take your medication. Ask your pharmacist any questions you have about refilling your prescription.

It is important for you to keep a written list of all of the prescription and nonprescription (over-the-counter) medicines you are taking, as well as any products such as vitamins, minerals, or other dietary supplements. You should bring this list with you each time you visit a doctor or if you are admitted to a hospital. It is also important information to carry with you in case of emergencies.

Drug Interaction
Moxifloxacin Moxifloxacin The risk or severity of QTc prolongation can be increased when Mirabegron is combined with Moxifloxacin.
Delavirdine Delavirdine The metabolism of Mirabegron can be decreased when combined with Delavirdine.
Nevirapine Nevirapine The metabolism of Mirabegron can be decreased when combined with Nevirapine.
Dolasetron Dolasetron The metabolism of Dolasetron can be decreased when combined with Mirabegron.
Anagrelide Anagrelide The risk or severity of QTc prolongation can be increased when Mirabegron is combined with Anagrelide.
Candesartan Candesartan Mirabegron may decrease the antihypertensive activities of Candesartan.
Cilostazol Cilostazol The metabolism of Mirabegron can be decreased when combined with Cilostazol.
Erythromycin and Sulfisoxazole Erythromycin and Sulfisoxazole The serum concentration of Mirabegron can be increased when it is combined with Erythromycin.
Estrogen and Progestin (Oral Contraceptives) Estrogen and Progestin (Oral Contraceptives) Conjugated estrogens may decrease the excretion rate of Mirabegron which could result in a higher serum level.
Fenofibrate Fenofibrate Fenofibrate may decrease the excretion rate of Mirabegron which could result in a higher serum level.
Guanfacine Guanfacine Guanfacine may decrease the excretion rate of Mirabegron which could result in a higher serum level.
Magnesium Hydroxide Magnesium Hydroxide Mirabegron may decrease the excretion rate of Magnesium hydroxide which could result in a higher serum level.
Methylergonovine Methylergonovine Methylergometrine may increase the hypertensive and vasoconstricting activities of Mirabegron.
Mycophenolate Mycophenolate Mycophenolic acid may decrease the excretion rate of Mirabegron which could result in a higher serum level.
Naratriptan Naratriptan The risk or severity of hypertension can be increased when Naratriptan is combined with Mirabegron.
Olsalazine Olsalazine Olsalazine may decrease the excretion rate of Mirabegron which could result in a higher serum level.
Paregoric Paregoric The serum concentration of Mirabegron can be increased when it is combined with Morphine.
Penbutolol Penbutolol The metabolism of Mirabegron can be decreased when combined with Acebutolol.
Potassium Potassium Potassium cation may increase the excretion rate of Mirabegron which could result in a lower serum level and potentially a reduction in efficacy.
Prednisone Prednisone Prednisone may decrease the excretion rate of Mirabegron which could result in a higher serum level.
Ranitidine Ranitidine The metabolism of Mirabegron can be decreased when combined with Ranitidine.
Reserpine Reserpine The serum concentration of Mirabegron can be increased when it is combined with Reserpine.
Rizatriptan Rizatriptan Rizatriptan may decrease the excretion rate of Mirabegron which could result in a higher serum level.
Sumatriptan Sumatriptan Sumatriptan may decrease the excretion rate of Mirabegron which could result in a higher serum level.
Tacrolimus Tacrolimus The serum concentration of Mirabegron can be increased when it is combined with Tacrolimus.
Tizanidine Tizanidine The risk or severity of QTc prolongation can be increased when Tizanidine is combined with Mirabegron.
Zolmitriptan Zolmitriptan The risk or severity of hypertension can be increased when Zolmitriptan is combined with Mirabegron.
Ampicillin Injection Ampicillin Injection Ampicillin may decrease the excretion rate of Mirabegron which could result in a higher serum level.
Doxycycline Injection Doxycycline Injection Doxycycline may decrease the excretion rate of Mirabegron which could result in a higher serum level.
Famotidine Injection Famotidine Injection The risk or severity of QTc prolongation can be increased when Famotidine is combined with Mirabegron.
Fluconazole Injection Fluconazole Injection The serum concentration of Mirabegron can be increased when it is combined with Fluconazole.
Foscarnet Injection Foscarnet Injection Foscarnet may decrease the excretion rate of Mirabegron which could result in a higher serum level.
Hydromorphone Injection Hydromorphone Injection Hydromorphone may decrease the excretion rate of Mirabegron which could result in a higher serum level.
Levofloxacin Injection Levofloxacin Injection The risk or severity of QTc prolongation can be increased when Levofloxacin is combined with Mirabegron.
Meperidine Injection Meperidine Injection The metabolism of Meperidine can be decreased when combined with Mirabegron.
Metoclopramide Injection Metoclopramide Injection The metabolism of Metoclopramide can be decreased when combined with Mirabegron.
Metronidazole Injection Metronidazole Injection The risk or severity of QTc prolongation can be increased when Metronidazole is combined with Mirabegron.
Morphine Injection Morphine Injection The serum concentration of Mirabegron can be increased when it is combined with Morphine.
Pamidronate Injection Pamidronate Injection Pamidronic acid may decrease the excretion rate of Mirabegron which could result in a higher serum level.
Vancomycin Injection Vancomycin Injection Mirabegron may decrease the excretion rate of Vancomycin which could result in a higher serum level.
Altretamine Altretamine The metabolism of Mirabegron can be decreased when combined with Amphetamine.
Cefuroxime Cefuroxime Cefuroxime may decrease the excretion rate of Mirabegron which could result in a higher serum level.
Cyclosporine Cyclosporine The metabolism of Cyclosporine can be decreased when combined with Mirabegron.
Ondansetron Ondansetron The metabolism of Ondansetron can be decreased when combined with Mirabegron.
Granisetron Granisetron The risk or severity of QTc prolongation can be increased when Mirabegron is combined with Granisetron.
Torsemide Torsemide Torasemide may increase the excretion rate of Mirabegron which could result in a lower serum level and potentially a reduction in efficacy.
Olanzapine Olanzapine The risk or severity of urinary retention can be increased when Olanzapine is combined with Mirabegron.
Dofetilide Dofetilide The risk or severity of QTc prolongation can be increased when Mirabegron is combined with Dofetilide.
Entacapone Entacapone The metabolism of Mirabegron can be decreased when combined with Entacapone.
Eprosartan Eprosartan Mirabegron may decrease the antihypertensive activities of Eprosartan.
Hydroxychloroquine Hydroxychloroquine The metabolism of Mirabegron can be decreased when combined with Hydroxychloroquine.
Meloxicam Meloxicam Meloxicam may decrease the excretion rate of Mirabegron which could result in a higher serum level.
Pantoprazole Pantoprazole Pantoprazole may decrease the excretion rate of Mirabegron which could result in a higher serum level.
Telmisartan Telmisartan Mirabegron may decrease the antihypertensive activities of Telmisartan.
Temozolomide Temozolomide Temozolomide may decrease the excretion rate of Mirabegron which could result in a higher serum level.
Zaleplon Zaleplon Zaleplon may decrease the excretion rate of Mirabegron which could result in a higher serum level.
Anakinra Anakinra The metabolism of Mirabegron can be increased when combined with Anakinra.
Desloratadine Desloratadine The risk or severity of QTc prolongation can be increased when Mirabegron is combined with Desloratadine.
Linezolid Linezolid The risk or severity of hypertension can be increased when Linezolid is combined with Mirabegron.
Rivastigmine Rivastigmine Rivastigmine may increase the neuromuscular blocking activities of Mirabegron.
Trimipramine Trimipramine The serum concentration of Mirabegron can be increased when it is combined with Trimipramine.
Etanercept Injection Etanercept Injection The metabolism of Mirabegron can be increased when combined with Etanercept.
Glycopyrrolate Glycopyrrolate The risk or severity of urinary retention can be increased when Glycopyrronium is combined with Mirabegron.
Perindopril Perindopril Mirabegron may decrease the antihypertensive activities of Perindopril.
Tenofovir Tenofovir Tenofovir may decrease the excretion rate of Mirabegron which could result in a higher serum level.
Choline Magnesium Trisalicylate Choline Magnesium Trisalicylate Choline magnesium trisalicylate may decrease the excretion rate of Mirabegron which could result in a higher serum level.
Sirolimus Sirolimus The serum concentration of Sirolimus can be increased when it is combined with Mirabegron.
Dutasteride Dutasteride The risk or severity of hypertension can be increased when Dutasteride is combined with Mirabegron.
Epinephrine Injection Epinephrine Injection The risk or severity of hypertension can be increased when Epinephrine is combined with Mirabegron.
Eplerenone Eplerenone Mirabegron may increase the excretion rate of Eplerenone which could result in a lower serum level and potentially a reduction in efficacy.
Escitalopram Escitalopram The risk or severity of urinary retention can be increased when Escitalopram is combined with Mirabegron.
Olmesartan Olmesartan Mirabegron may decrease the antihypertensive activities of Olmesartan.
Zonisamide Zonisamide The serum concentration of Mirabegron can be increased when it is combined with Zonisamide.
Adalimumab Injection Adalimumab Injection The metabolism of Mirabegron can be increased when combined with Adalimumab.
Aripiprazole Aripiprazole The risk or severity of urinary retention can be increased when Aripiprazole is combined with Mirabegron.
Atomoxetine Atomoxetine The metabolism of Mirabegron can be decreased when combined with Atomoxetine.
Dexmethylphenidate Dexmethylphenidate The risk or severity of hypertension can be increased when Dexmethylphenidate is combined with Mirabegron.
Atazanavir Atazanavir Atazanavir may decrease the excretion rate of Mirabegron which could result in a higher serum level.
Almotriptan Almotriptan The metabolism of Mirabegron can be decreased when combined with Almotriptan.
Eletriptan Eletriptan The metabolism of Eletriptan can be decreased when combined with Mirabegron.
Mefloquine Mefloquine The risk or severity of QTc prolongation can be increased when Mefloquine is combined with Mirabegron.
Vardenafil Vardenafil The serum concentration of Vardenafil can be increased when it is combined with Mirabegron.
Alfuzosin Alfuzosin The therapeutic efficacy of Mirabegron can be decreased when used in combination with Alfuzosin.
Emtricitabine Emtricitabine Emtricitabine may decrease the excretion rate of Mirabegron which could result in a higher serum level.
Memantine Memantine Memantine may increase the neuromuscular blocking activities of Mirabegron.
Tegaserod Tegaserod The metabolism of Mirabegron can be decreased when combined with Tegaserod.
Tadalafil Tadalafil Mirabegron may decrease the excretion rate of Tadalafil which could result in a higher serum level.
Frovatriptan Frovatriptan The risk or severity of hypertension can be increased when Frovatriptan is combined with Mirabegron.
Gemifloxacin Gemifloxacin The risk or severity of QTc prolongation can be increased when Mirabegron is combined with Gemifloxacin.
Progesterone Progesterone The metabolism of Mirabegron can be decreased when combined with Progesterone.
Apomorphine Injection Apomorphine Injection The risk or severity of QTc prolongation can be increased when Apomorphine is combined with Mirabegron.
Infliximab Injection Infliximab Injection The metabolism of Mirabegron can be increased when combined with Infliximab.
Protriptyline Protriptyline The metabolism of Mirabegron can be decreased when combined with Protriptyline.
Rifaximin Rifaximin The serum concentration of Rifaximin can be increased when it is combined with Mirabegron.
Duloxetine Duloxetine The metabolism of Mirabegron can be decreased when combined with Duloxetine.
Tinidazole Tinidazole Tinidazole may decrease the excretion rate of Mirabegron which could result in a higher serum level.
Trospium Trospium The risk or severity of urinary retention can be increased when Trospium is combined with Mirabegron.
Bosentan Bosentan Mirabegron may decrease the antihypertensive activities of Bosentan.
Cefditoren Cefditoren Cefdinir may decrease the excretion rate of Mirabegron which could result in a higher serum level.
Cinacalcet Cinacalcet The metabolism of Mirabegron can be decreased when combined with Cinacalcet.
Cyanocobalamin Injection Cyanocobalamin Injection Hydroxocobalamin may decrease the excretion rate of Mirabegron which could result in a higher serum level.
Erlotinib Erlotinib The serum concentration of Erlotinib can be increased when it is combined with Mirabegron.
Eszopiclone Eszopiclone Eszopiclone may decrease the excretion rate of Mirabegron which could result in a higher serum level.
Ganciclovir Ganciclovir Ganciclovir may decrease the excretion rate of Mirabegron which could result in a higher serum level.
Ribavirin Ribavirin Ribavirin may decrease the excretion rate of Mirabegron which could result in a higher serum level.
Solifenacin Solifenacin The risk or severity of adverse effects can be increased when Mirabegron is combined with Solifenacin.
Valganciclovir Valganciclovir Valganciclovir may decrease the excretion rate of Mirabegron which could result in a higher serum level.
Voriconazole Voriconazole The risk or severity of QTc prolongation can be increased when Voriconazole is combined with Mirabegron.
Adefovir Adefovir Adefovir may decrease the excretion rate of Mirabegron which could result in a higher serum level.
Dextroamphetamine Dextroamphetamine The metabolism of Mirabegron can be decreased when combined with Amphetamine.
Peginterferon Alfa-2b (PEG-Intron) Peginterferon Alfa-2b (PEG-Intron) The metabolism of Mirabegron can be decreased when combined with Peginterferon alfa-2b.
Ibandronate Ibandronate The risk or severity of QTc prolongation can be increased when Ibandronate is combined with Mirabegron.
Isocarboxazid Isocarboxazid The risk or severity of hypertension can be increased when Isocarboxazid is combined with Mirabegron.
Ramelteon Ramelteon Ramelteon may decrease the excretion rate of Mirabegron which could result in a higher serum level.
Darifenacin Darifenacin The risk or severity of urinary retention can be increased when Darifenacin is combined with Mirabegron.
Fentanyl Fentanyl The risk or severity of hypertension can be increased when Fentanyl is combined with Mirabegron.
Pregabalin Pregabalin The risk or severity of QTc prolongation can be increased when Pregabalin is combined with Mirabegron.
Phenylephrine Phenylephrine The risk or severity of hypertension can be increased when Phenylephrine is combined with Mirabegron.
Tipranavir Tipranavir The metabolism of Tipranavir can be decreased when combined with Mirabegron.
Felbamate Felbamate The risk or severity of QTc prolongation can be increased when Felbamate is combined with Mirabegron.
Ranolazine Ranolazine The serum concentration of Mirabegron can be increased when it is combined with Ranolazine.
Abatacept Injection Abatacept Injection The metabolism of Mirabegron can be increased when combined with Abatacept.
Rasagiline Rasagiline Rasagiline may decrease the excretion rate of Mirabegron which could result in a higher serum level.
Imatinib Imatinib The metabolism of Imatinib can be decreased when combined with Mirabegron.
Sitagliptin Sitagliptin The serum concentration of Mirabegron can be increased when it is combined with Sitagliptin.
Varenicline Varenicline Varenicline may decrease the excretion rate of Mirabegron which could result in a higher serum level.
Gefitinib Gefitinib The metabolism of Mirabegron can be decreased when combined with Gefitinib.
Albuterol Albuterol The risk or severity of QTc prolongation can be increased when Salbutamol is combined with Mirabegron.
Paliperidone Paliperidone The metabolism of Paliperidone can be decreased when combined with Mirabegron.
Bortezomib Bortezomib The metabolism of Mirabegron can be decreased when combined with Bortezomib.
Clofarabine Injection Clofarabine Injection Clofarabine may decrease the excretion rate of Mirabegron which could result in a higher serum level.
Lubiprostone Lubiprostone Lubiprostone may decrease the excretion rate of Mirabegron which could result in a higher serum level.
Oxaliplatin Injection Oxaliplatin Injection The risk or severity of QTc prolongation can be increased when Mirabegron is combined with Oxaliplatin.
Posaconazole Posaconazole The serum concentration of Mirabegron can be increased when it is combined with Posaconazole.
Primaquine Primaquine The metabolism of Mirabegron can be decreased when combined with Primaquine.
Aliskiren Aliskiren Mirabegron may decrease the antihypertensive activities of Aliskiren.
Pemetrexed Injection Pemetrexed Injection Mirabegron may decrease the excretion rate of Pemetrexed which could result in a higher serum level.
Dimenhydrinate Dimenhydrinate The risk or severity of QTc prolongation can be increased when Mirabegron is combined with Dimenhydrinate.
Lisdexamfetamine Lisdexamfetamine The metabolism of Mirabegron can be decreased when combined with Lisdexamfetamine.
Nabilone Nabilone The risk or severity of Tachycardia can be increased when Nabilone is combined with Mirabegron.
Vorinostat Vorinostat The risk or severity of QTc prolongation can be increased when Vorinostat is combined with Mirabegron.
Sorafenib Sorafenib The serum concentration of Mirabegron can be increased when it is combined with Sorafenib.
Sunitinib Sunitinib The risk or severity of QTc prolongation can be increased when Sunitinib is combined with Mirabegron.
Dronabinol Dronabinol The risk or severity of Tachycardia can be increased when Dronabinol is combined with Mirabegron.
Lapatinib Lapatinib The serum concentration of Mirabegron can be increased when it is combined with Lapatinib.
Levocetirizine Levocetirizine The risk or severity of QTc prolongation can be increased when Levocetirizine is combined with Mirabegron.
Pegaptanib Injection Pegaptanib Injection Pegaptanib may decrease the excretion rate of Mirabegron which could result in a higher serum level.
Dasatinib Dasatinib The serum concentration of Dasatinib can be increased when it is combined with Mirabegron.
Mexiletine Mexiletine The metabolism of Mirabegron can be decreased when combined with Mexiletine.
Azacitidine Injection Azacitidine Injection Azacitidine may decrease the excretion rate of Mirabegron which could result in a higher serum level.
Temsirolimus Temsirolimus The serum concentration of Temsirolimus can be increased when it is combined with Mirabegron.
Lenalidomide Lenalidomide Lenalidomide may decrease the excretion rate of Mirabegron which could result in a higher serum level.
Nilotinib Nilotinib The metabolism of Nilotinib can be decreased when combined with Mirabegron.
Toremifene Toremifene The risk or severity of QTc prolongation can be increased when Mirabegron is combined with Toremifene.
Budesonide Budesonide Budesonide may decrease the excretion rate of Mirabegron which could result in a higher serum level.
Desmopressin Desmopressin Desmopressin may decrease the excretion rate of Mirabegron which could result in a higher serum level.
Betaine Betaine Glycine betaine may increase the neuromuscular blocking activities of Mirabegron.
Doripenem Injection Doripenem Injection Doripenem may decrease the excretion rate of Mirabegron which could result in a higher serum level.
Arsenic Trioxide Injection Arsenic Trioxide Injection The risk or severity of QTc prolongation can be increased when Mirabegron is combined with Arsenic trioxide.
Desvenlafaxine Desvenlafaxine Desvenlafaxine may increase the tachycardic activities of Mirabegron.
Cevimeline Cevimeline The metabolism of Mirabegron can be decreased when combined with Cevimeline.
Nebivolol Nebivolol The metabolism of Mirabegron can be decreased when combined with Nebivolol.
Bendamustine Injection Bendamustine Injection The serum concentration of Bendamustine can be increased when it is combined with Mirabegron.
Flecainide Flecainide The serum concentration of Flecainide can be increased when it is combined with Mirabegron.
Certolizumab Injection Certolizumab Injection The metabolism of Certolizumab pegol can be increased when combined with Mirabegron.
Irinotecan Injection Irinotecan Injection The serum concentration of Mirabegron can be increased when it is combined with Irinotecan.
Daptomycin Injection Daptomycin Injection Daptomycin may decrease the excretion rate of Mirabegron which could result in a higher serum level.
Methylnaltrexone Injection Methylnaltrexone Injection Methylnaltrexone may decrease the excretion rate of Mirabegron which could result in a higher serum level.
Silodosin Silodosin The serum concentration of Silodosin can be increased when it is combined with Mirabegron.
Midazolam Midazolam Midazolam may decrease the excretion rate of Mirabegron which could result in a higher serum level.
Dexrazoxane Injection Dexrazoxane Injection Dexrazoxane may decrease the excretion rate of Mirabegron which could result in a higher serum level.
Milnacipran Milnacipran Milnacipran may increase the tachycardic activities of Mirabegron.
Plerixafor Injection Plerixafor Injection Plerixafor may decrease the excretion rate of Mirabegron which could result in a higher serum level.
Fesoterodine Fesoterodine The risk or severity of urinary retention can be increased when Fesoterodine is combined with Mirabegron.
Degarelix Injection Degarelix Injection The risk or severity of QTc prolongation can be increased when Degarelix is combined with Mirabegron.
Betaxolol Betaxolol The metabolism of Mirabegron can be decreased when combined with Betaxolol.
Iloperidone Iloperidone The metabolism of Iloperidone can be decreased when combined with Mirabegron.
Prasugrel Prasugrel Prasugrel may decrease the excretion rate of Mirabegron which could result in a higher serum level.
Everolimus Everolimus The serum concentration of Everolimus can be increased when it is combined with Mirabegron.
Tolvaptan (low blood sodium) Tolvaptan (low blood sodium) The serum concentration of Tolvaptan can be increased when it is combined with Mirabegron.
Dronedarone Dronedarone The metabolism of Dronedarone can be decreased when combined with Mirabegron.
Pralatrexate Injection Pralatrexate Injection Pralatrexate may decrease the excretion rate of Mirabegron which could result in a higher serum level.
Palonosetron Injection Palonosetron Injection The metabolism of Mirabegron can be decreased when combined with Palonosetron.
Saxagliptin Saxagliptin Saxagliptin may decrease the excretion rate of Mirabegron which could result in a higher serum level.
Telavancin Injection Telavancin Injection The risk or severity of QTc prolongation can be increased when Mirabegron is combined with Telavancin.
Romidepsin Injection Romidepsin Injection The serum concentration of Romidepsin can be increased when it is combined with Mirabegron.
Tapentadol Tapentadol The metabolism of Mirabegron can be decreased when combined with Tapentadol.
Topotecan Topotecan The serum concentration of Topotecan can be increased when it is combined with Mirabegron.
Golimumab Injection Golimumab Injection The metabolism of Mirabegron can be increased when combined with Golimumab.
Pazopanib Pazopanib The serum concentration of Pazopanib can be increased when it is combined with Mirabegron.
Asenapine Asenapine The risk or severity of QTc prolongation can be increased when Mirabegron is combined with Asenapine.
Oxymorphone Oxymorphone The metabolism of Mirabegron can be decreased when combined with Oxymorphone.
Tocilizumab Injection Tocilizumab Injection The metabolism of Mirabegron can be increased when combined with Tocilizumab.
Dalfampridine Dalfampridine Dalfampridine may decrease the excretion rate of Mirabegron which could result in a higher serum level.
Eribulin Injection Eribulin Injection The risk or severity of QTc prolongation can be increased when Eribulin is combined with Mirabegron.
Cabazitaxel Injection Cabazitaxel Injection The serum concentration of Mirabegron can be increased when it is combined with Cabazitaxel.
Ceftaroline Injection Ceftaroline Injection Ceftaroline fosamil may decrease the excretion rate of Mirabegron which could result in a higher serum level.
Lurasidone Lurasidone The risk or severity of QTc prolongation can be increased when Lurasidone is combined with Mirabegron.
Acetaminophen Injection Acetaminophen Injection The metabolism of Mirabegron can be decreased when combined with Acetaminophen.
Vilazodone Vilazodone The metabolism of Mirabegron can be decreased when combined with Vilazodone.
Ipilimumab Injection Ipilimumab Injection Ipilimumab may decrease the excretion rate of Mirabegron which could result in a higher serum level.
Denileukin Diftitox Injection Denileukin Diftitox Injection Aldesleukin may decrease the excretion rate of Mirabegron which could result in a higher serum level.
Terbutaline Injection Terbutaline Injection The risk or severity of QTc prolongation can be increased when Terbutaline is combined with Mirabegron.
Roflumilast Roflumilast Roflumilast may decrease the excretion rate of Mirabegron which could result in a higher serum level.
Linagliptin Linagliptin The serum concentration of Mirabegron can be increased when it is combined with Linagliptin.
Rilpivirine Rilpivirine The metabolism of Rilpivirine can be decreased when combined with Mirabegron.
Telaprevir Telaprevir The serum concentration of Glecaprevir can be increased when it is combined with Mirabegron.
Abiraterone Abiraterone The metabolism of Mirabegron can be decreased when combined with Abiraterone.
Triptorelin Injection Triptorelin Injection The risk or severity of QTc prolongation can be increased when Triptorelin is combined with Mirabegron.
Rivaroxaban Rivaroxaban The serum concentration of Rivaroxaban can be increased when it is combined with Mirabegron.
Ticagrelor Ticagrelor The serum concentration of Mirabegron can be increased when it is combined with Ticagrelor.
Brentuximab Vedotin Injection Brentuximab Vedotin Injection The serum concentration of Brentuximab vedotin can be increased when it is combined with Mirabegron.
Ruxolitinib Ruxolitinib Ruxolitinib may decrease the excretion rate of Mirabegron which could result in a higher serum level.
Vandetanib Vandetanib The risk or severity of QTc prolongation can be increased when Mirabegron is combined with Vandetanib.
Clobazam Clobazam The metabolism of Mirabegron can be decreased when combined with Clobazam.
Vemurafenib Vemurafenib The serum concentration of Mirabegron can be increased when it is combined with Vemurafenib.
Ivacaftor Ivacaftor The serum concentration of Mirabegron can be increased when it is combined with Ivacaftor.
Deferiprone Deferiprone Deferiprone may decrease the excretion rate of Mirabegron which could result in a higher serum level.
Axitinib Axitinib The serum concentration of Axitinib can be increased when it is combined with Mirabegron.
Crizotinib Crizotinib The serum concentration of Mirabegron can be increased when it is combined with Crizotinib.
Cabergoline Cabergoline The serum concentration of Mirabegron can be increased when it is combined with Cabergoline.
Naloxone Injection Naloxone Injection Naloxone may decrease the excretion rate of Mirabegron which could result in a higher serum level.
Ambrisentan Ambrisentan The serum concentration of Mirabegron can be increased when it is combined with Ambrisentan.
Fondaparinux Injection Fondaparinux Injection Fondaparinux may decrease the excretion rate of Mirabegron which could result in a higher serum level.
Carfilzomib Injection Carfilzomib Injection The serum concentration of Mirabegron can be increased when it is combined with Carfilzomib.
Enzalutamide Enzalutamide The serum concentration of Mirabegron can be increased when it is combined with Enzalutamide.
Regorafenib Regorafenib The serum concentration of Regorafenib can be increased when it is combined with Mirabegron.
Bosutinib Bosutinib The serum concentration of Bosutinib can be increased when it is combined with Mirabegron.
Teduglutide Injection Teduglutide Injection Mirabegron may decrease the excretion rate of Teduglutide which could result in a higher serum level.
Bedaquiline Bedaquiline The risk or severity of QTc prolongation can be increased when Mirabegron is combined with Bedaquiline.
Alogliptin Alogliptin The metabolism of Mirabegron can be decreased when combined with Alogliptin.
Ponatinib Ponatinib The serum concentration of Ponatinib can be increased when it is combined with Mirabegron.
Pomalidomide Pomalidomide The serum concentration of Pomalidomide can be increased when it is combined with Mirabegron.
Ado-trastuzumab Emtansine Injection Ado-trastuzumab Emtansine Injection The serum concentration of Trastuzumab emtansine can be increased when it is combined with Mirabegron.
Apixaban Apixaban The serum concentration of Mirabegron can be increased when it is combined with Apixaban.
Canagliflozin Canagliflozin The serum concentration of Canagliflozin can be increased when it is combined with Mirabegron.
Methazolamide Methazolamide Methazolamide may increase the excretion rate of Mirabegron which could result in a lower serum level and potentially a reduction in efficacy.
Dabrafenib Dabrafenib The serum concentration of Dabrafenib can be increased when it is combined with Mirabegron.
Ospemifene Ospemifene The metabolism of Mirabegron can be decreased when combined with Ospemifene.
Trametinib Trametinib Mirabegron may decrease the excretion rate of Trametinib which could result in a higher serum level.
Dolutegravir Dolutegravir The serum concentration of Dolutegravir can be increased when it is combined with Mirabegron.
Afatinib Afatinib The serum concentration of Afatinib can be increased when it is combined with Mirabegron.
Levomilnacipran Levomilnacipran The metabolism of Levomilnacipran can be decreased when combined with Mirabegron.
Ertapenem Injection Ertapenem Injection Ertapenem may decrease the excretion rate of Mirabegron which could result in a higher serum level.
Vortioxetine Vortioxetine The metabolism of Vortioxetine can be decreased when combined with Mirabegron.
Ibrutinib Ibrutinib The metabolism of Ibrutinib can be decreased when combined with Mirabegron.
Lomitapide Lomitapide The serum concentration of Lomitapide can be increased when it is combined with Mirabegron.
Ketorolac Injection Ketorolac Injection Ketorolac may decrease the excretion rate of Mirabegron which could result in a higher serum level.
Simeprevir Simeprevir The serum concentration of Mirabegron can be increased when it is combined with Simeprevir.
Sofosbuvir Sofosbuvir The serum concentration of Sofosbuvir can be increased when it is combined with Mirabegron.
Dapagliflozin Dapagliflozin The metabolism of Dapagliflozin can be decreased when combined with Mirabegron.
Apremilast Apremilast The metabolism of Mirabegron can be increased when combined with Apremilast.
Droxidopa Droxidopa Droxidopa may decrease the excretion rate of Mirabegron which could result in a higher serum level.
Ceritinib Ceritinib The serum concentration of Ceritinib can be increased when it is combined with Mirabegron.
Siltuximab Injection Siltuximab Injection The metabolism of Mirabegron can be increased when combined with Siltuximab.
Belinostat Injection Belinostat Injection The serum concentration of Mirabegron can be increased when it is combined with Belinostat.
Idelalisib Idelalisib The serum concentration of Idelalisib can be increased when it is combined with Mirabegron.
Testosterone Injection Testosterone Injection Testosterone may decrease the excretion rate of Mirabegron which could result in a higher serum level.
Oritavancin Injection Oritavancin Injection The metabolism of Mirabegron can be decreased when combined with Oritavancin.
Vorapaxar Vorapaxar The serum concentration of Mirabegron can be increased when it is combined with Vorapaxar.
Hydrocodone Hydrocodone The metabolism of Mirabegron can be decreased when combined with Hydrocodone.
Suvorexant Suvorexant The serum concentration of Mirabegron can be increased when it is combined with Suvorexant.
Edoxaban Edoxaban The serum concentration of Edoxaban can be increased when it is combined with Mirabegron.
Methamphetamine Methamphetamine The metabolism of Mirabegron can be decreased when combined with Metamfetamine.
Tasimelteon Tasimelteon Mirabegron may decrease the excretion rate of Tasimelteon which could result in a higher serum level.
Riociguat Riociguat Mirabegron may decrease the antihypertensive activities of Riociguat.
Nintedanib Nintedanib The serum concentration of Nintedanib can be increased when it is combined with Mirabegron.
Secukinumab Injection Secukinumab Injection The metabolism of Mirabegron can be increased when combined with Secukinumab.
Risperidone Injection Risperidone Injection The metabolism of Risperidone can be decreased when combined with Mirabegron.
Palbociclib Palbociclib The serum concentration of Palbociclib can be increased when it is combined with Mirabegron.
Lenvatinib Lenvatinib The risk or severity of QTc prolongation can be increased when Mirabegron is combined with Lenvatinib.
Naloxegol Naloxegol The serum concentration of Naloxegol can be increased when it is combined with Mirabegron.
Panobinostat Panobinostat The metabolism of Mirabegron can be decreased when combined with Panobinostat.
Haloperidol Injection Haloperidol Injection The risk or severity of QTc prolongation can be increased when Haloperidol is combined with Mirabegron.
Ivabradine Ivabradine The risk or severity of QTc prolongation can be increased when Mirabegron is combined with Ivabradine.
Amiloride Amiloride Amiloride may increase the excretion rate of Mirabegron which could result in a lower serum level and potentially a reduction in efficacy.
Isavuconazonium Injection Isavuconazonium Injection The serum concentration of Mirabegron can be increased when it is combined with Isavuconazonium.
Macitentan Macitentan Mirabegron may decrease the excretion rate of Macitentan which could result in a higher serum level.
Flibanserin Flibanserin The serum concentration of Mirabegron can be increased when it is combined with Flibanserin.
Rolapitant Rolapitant The metabolism of Mirabegron can be decreased when combined with Rolapitant.
Daclatasvir Daclatasvir The serum concentration of Mirabegron can be increased when it is combined with Daclatasvir.
Brexpiprazole Brexpiprazole The metabolism of Brexpiprazole can be decreased when combined with Mirabegron.
Ziprasidone Injection Ziprasidone Injection The risk or severity of QTc prolongation can be increased when Ziprasidone is combined with Mirabegron.
Cariprazine Cariprazine The metabolism of Mirabegron can be decreased when combined with Cariprazine.
Penicillin G Procaine Injection Penicillin G Procaine Injection Mirabegron may decrease the excretion rate of Procaine benzylpenicillin which could result in a higher serum level.
Cobimetinib Cobimetinib The serum concentration of Mirabegron can be increased when it is combined with Cobimetinib.
Trabectedin Injection Trabectedin Injection The serum concentration of Mirabegron can be increased when it is combined with Trabectedin.
Osimertinib Osimertinib The serum concentration of Osimertinib can be increased when it is combined with Mirabegron.
Ixazomib Ixazomib Mirabegron may decrease the excretion rate of Ixazomib which could result in a higher serum level.
Lesinurad Lesinurad Mirabegron may decrease the excretion rate of Lesinurad which could result in a higher serum level.
Amphotericin B Liposomal Injection Amphotericin B Liposomal Injection Amphotericin B may decrease the excretion rate of Mirabegron which could result in a higher serum level.
Brivaracetam Injection Brivaracetam Injection Brivaracetam may decrease the excretion rate of Mirabegron which could result in a higher serum level.
Venetoclax Venetoclax The serum concentration of Venetoclax can be increased when it is combined with Mirabegron.
Cobicistat Cobicistat The serum concentration of Mirabegron can be increased when it is combined with Cobicistat.
Midodrine Midodrine The risk or severity of hypertension can be increased when Midodrine is combined with Mirabegron.
Selexipag Selexipag The serum concentration of Selexipag can be increased when it is combined with Mirabegron.
Diphenhydramine Injection Diphenhydramine Injection The risk or severity of urinary retention can be increased when Diphenhydramine is combined with Mirabegron.
Furosemide Injection Furosemide Injection Furosemide may increase the excretion rate of Mirabegron which could result in a lower serum level and potentially a reduction in efficacy.
Rucaparib Rucaparib The metabolism of Rucaparib can be decreased when combined with Mirabegron.
Lixisenatide Injection Lixisenatide Injection Mirabegron may decrease the excretion rate of Lixisenatide which could result in a higher serum level.
Ribociclib Ribociclib The risk or severity of QTc prolongation can be increased when Mirabegron is combined with Ribociclib.
Doxepin (Insomnia) Doxepin (Insomnia) The risk or severity of urinary retention can be increased when Doxepin is combined with Mirabegron.
Deutetrabenazine Deutetrabenazine The metabolism of Deutetrabenazine can be decreased when combined with Mirabegron.
Valbenazine Valbenazine The metabolism of Valbenazine can be decreased when combined with Mirabegron.
Safinamide Safinamide The metabolism of Mirabegron can be decreased when combined with Safinamide.
Naldemedine Naldemedine Mirabegron may decrease the excretion rate of Naldemedine which could result in a higher serum level.
Midostaurin Midostaurin The metabolism of Mirabegron can be decreased when combined with Midostaurin.
Neratinib Neratinib The serum concentration of Mirabegron can be increased when it is combined with Neratinib.
Enasidenib Enasidenib The serum concentration of Mirabegron can be increased when it is combined with Enasidenib.
Inotuzumab Ozogamicin Injection Inotuzumab Ozogamicin Injection The serum concentration of Mirabegron can be increased when it is combined with Inotuzumab ozogamicin.
Benznidazole Benznidazole Mirabegron may decrease the excretion rate of Benznidazole which could result in a higher serum level.
Copanlisib Injection Copanlisib Injection The serum concentration of Copanlisib can be increased when it is combined with Mirabegron.
Delafloxacin Delafloxacin The risk or severity of QTc prolongation can be increased when Mirabegron is combined with Delafloxacin.
Abemaciclib Abemaciclib The serum concentration of Abemaciclib can be increased when it is combined with Mirabegron.
Betrixaban Betrixaban The serum concentration of Betrixaban can be increased when it is combined with Mirabegron.
Letermovir Letermovir The metabolism of Letermovir can be decreased when combined with Mirabegron.
Tetrabenazine Tetrabenazine The metabolism of Tetrabenazine can be decreased when combined with Mirabegron.
Ertugliflozin Ertugliflozin The serum concentration of Ertugliflozin can be increased when it is combined with Mirabegron.
Buprenorphine Injection Buprenorphine Injection The metabolism of Mirabegron can be decreased when combined with Buprenorphine.
Apalutamide Apalutamide The serum concentration of Mirabegron can be decreased when it is combined with Apalutamide.
Avatrombopag Avatrombopag The serum concentration of Avatrombopag can be increased when it is combined with Mirabegron.
Baricitinib Baricitinib The serum concentration of Baricitinib can be increased when it is combined with Mirabegron.
Lofexidine Lofexidine The metabolism of Mirabegron can be decreased when combined with Lofexidine.
Plazomicin Injection Plazomicin Injection Mirabegron may decrease the excretion rate of Plazomicin which could result in a higher serum level.
Eliglustat Eliglustat The metabolism of Eliglustat can be decreased when combined with Mirabegron.
Encorafenib Encorafenib The metabolism of Encorafenib can be decreased when combined with Mirabegron.
Binimetinib Binimetinib The serum concentration of Binimetinib can be increased when it is combined with Mirabegron.
Ivosidenib Ivosidenib The serum concentration of Ivosidenib can be increased when it is combined with Mirabegron.
Lusutrombopag Lusutrombopag The serum concentration of Lusutrombopag can be increased when it is combined with Mirabegron.
Elagolix Elagolix The metabolism of Elagolix can be decreased when combined with Mirabegron.
Tafenoquine Tafenoquine The metabolism of Mirabegron can be decreased when combined with Tafenoquine.
Cannabidiol Cannabidiol The metabolism of Cannabidiol can be decreased when combined with Mirabegron.
Dacomitinib Dacomitinib The serum concentration of Mirabegron can be increased when it is combined with Dacomitinib.
Duvelisib Duvelisib The serum concentration of Duvelisib can be increased when it is combined with Mirabegron.
Omadacycline Omadacycline The serum concentration of Omadacycline can be increased when it is combined with Mirabegron.
Sarecycline Sarecycline The serum concentration of Mirabegron can be increased when it is combined with Sarecycline.
Stiripentol Stiripentol The metabolism of Mirabegron can be decreased when combined with Stiripentol.
Talazoparib Talazoparib The serum concentration of Talazoparib can be increased when it is combined with Mirabegron.
Gilteritinib Gilteritinib The risk or severity of QTc prolongation can be increased when Mirabegron is combined with Gilteritinib.
Glasdegib Glasdegib The risk or severity of QTc prolongation can be increased when Mirabegron is combined with Glasdegib.
Larotrectinib Larotrectinib The serum concentration of Larotrectinib can be increased when it is combined with Mirabegron.
Rifamycin Rifamycin The serum concentration of Rifamycin can be increased when it is combined with Mirabegron.
Prucalopride Prucalopride The serum concentration of Prucalopride can be increased when it is combined with Mirabegron.
Emapalumab-lzsg Injection Emapalumab-lzsg Injection The metabolism of Mirabegron can be increased when combined with Emapalumab.
Siponimod Siponimod The risk or severity of hypertension can be increased when Mirabegron is combined with Siponimod.
Acyclovir Ophthalmic Acyclovir Ophthalmic Acyclovir may decrease the excretion rate of Mirabegron which could result in a higher serum level.
Erdafitinib Erdafitinib The serum concentration of Mirabegron can be increased when it is combined with Erdafitinib.
Solriamfetol Solriamfetol The risk or severity of hypertension can be increased when Solriamfetol is combined with Mirabegron.
Darolutamide Darolutamide The serum concentration of Darolutamide can be increased when it is combined with Mirabegron.
Triclabendazole Triclabendazole The metabolism of Mirabegron can be decreased when combined with Triclabendazole.
Entrectinib Entrectinib The risk or severity of QTc prolongation can be increased when Mirabegron is combined with Entrectinib.
Istradefylline Istradefylline The metabolism of Mirabegron can be decreased when combined with Istradefylline.
Pitolisant Pitolisant The serum concentration of Mirabegron can be decreased when it is combined with Pitolisant.
Fedratinib Fedratinib The serum concentration of Fedratinib can be increased when it is combined with Mirabegron.
Lefamulin Lefamulin Mirabegron may increase the QTc-prolonging activities of Lefamulin.
Phenytoin Injection Phenytoin Injection The metabolism of Phenytoin can be decreased when combined with Mirabegron.
Enfortumab vedotin-ejfv Injection Enfortumab vedotin-ejfv Injection The serum concentration of Enfortumab vedotin can be increased when it is combined with Mirabegron.
Lasmiditan Lasmiditan The serum concentration of Mirabegron can be increased when it is combined with Lasmiditan.
Ubrogepant Ubrogepant The serum concentration of Ubrogepant can be increased when it is combined with Mirabegron.
Tazemetostat Tazemetostat The serum concentration of Tazemetostat can be increased when it is combined with Mirabegron.
Cenobamate Cenobamate The serum concentration of Mirabegron can be decreased when it is combined with Cenobamate.
Selumetinib Selumetinib The serum concentration of Selumetinib can be increased when it is combined with Mirabegron.
Rimegepant Rimegepant The serum concentration of Rimegepant can be increased when it is combined with Mirabegron.
Tucatinib Tucatinib Mirabegron may decrease the excretion rate of Tucatinib which could result in a higher serum level.
Remdesivir Injection Remdesivir Injection The serum concentration of Remdesivir can be increased when it is combined with Mirabegron.
Ripretinib Ripretinib The serum concentration of Ripretinib can be increased when it is combined with Mirabegron.
Selpercatinib Selpercatinib The risk or severity of hypertension can be increased when Mirabegron is combined with Selpercatinib.
Lemborexant Lemborexant The serum concentration of Lemborexant can be increased when it is combined with Mirabegron.
Fenfluramine Fenfluramine The metabolism of Mirabegron can be decreased when combined with Fenfluramine.
Fostemsavir Fostemsavir The serum concentration of Fostemsavir can be increased when it is combined with Mirabegron.
Octreotide Octreotide The risk or severity of QTc prolongation can be increased when Octreotide is combined with Mirabegron.
Belantamab Mafodotin-blmf Injection Belantamab Mafodotin-blmf Injection The serum concentration of Belantamab mafodotin can be increased when it is combined with Mirabegron.
Pralsetinib Pralsetinib The serum concentration of Pralsetinib can be increased when it is combined with Mirabegron.
Satralizumab-mwge Injection Satralizumab-mwge Injection The serum concentration of Mirabegron can be decreased when it is combined with Satralizumab.
Naxitamab-gqgk Injection Naxitamab-gqgk Injection The risk or severity of hypertension can be increased when Mirabegron is combined with Naxitamab.
Relugolix Relugolix The serum concentration of Relugolix can be increased when it is combined with Mirabegron.
Progestin-Only (drospirenone) Oral Contraceptives Progestin-Only (drospirenone) Oral Contraceptives Drospirenone may increase the excretion rate of Mirabegron which could result in a lower serum level and potentially a reduction in efficacy.
Vibegron Vibegron Mirabegron may increase the smooth muscle relaxing activities of Vibegron.
Viloxazine Viloxazine Mirabegron may decrease the excretion rate of Viloxazine which could result in a higher serum level.
Tobramycin Injection Tobramycin Injection Tobramycin may decrease the excretion rate of Mirabegron which could result in a higher serum level.
Theophylline Theophylline The serum concentration of Theophylline can be increased when it is combined with Mirabegron.
Fenoprofen Fenoprofen Fenoprofen may decrease the excretion rate of Mirabegron which could result in a higher serum level.
Indomethacin Indomethacin Indomethacin may decrease the excretion rate of Mirabegron which could result in a higher serum level.
Mefenamic Acid Mefenamic Acid Mefenamic acid may decrease the excretion rate of Mirabegron which could result in a higher serum level.
Naproxen Naproxen Naproxen may decrease the excretion rate of Mirabegron which could result in a higher serum level.
Tolmetin Tolmetin Tolmetin may decrease the excretion rate of Mirabegron which could result in a higher serum level.
Sulindac Sulindac Sulindac may decrease the excretion rate of Mirabegron which could result in a higher serum level.
Trazodone Trazodone The risk or severity of QTc prolongation can be increased when Trazodone is combined with Mirabegron.
Isotretinoin Isotretinoin Isotretinoin may decrease the excretion rate of Mirabegron which could result in a higher serum level.
Sucralfate Sucralfate Sucralfate may decrease the excretion rate of Mirabegron which could result in a higher serum level.
Hydroxyurea Hydroxyurea The metabolism of Mirabegron can be decreased when combined with Hydroxyurea.
Floxuridine Floxuridine Floxuridine may decrease the excretion rate of Mirabegron which could result in a higher serum level.
Metaxalone Metaxalone Metaxalone may decrease the excretion rate of Mirabegron which could result in a higher serum level.
Methotrexate Injection Methotrexate Injection Methotrexate may decrease the excretion rate of Mirabegron which could result in a higher serum level.
Methsuximide Methsuximide The risk or severity of QTc prolongation can be increased when Methsuximide is combined with Mirabegron.
Diethylpropion Diethylpropion The risk or severity of hypertension can be increased when Diethylpropion is combined with Mirabegron.
Chlorpromazine Chlorpromazine The risk or severity of urinary retention can be increased when Chlorpromazine is combined with Mirabegron.
Diazepam Diazepam Diazepam may decrease the excretion rate of Mirabegron which could result in a higher serum level.
Oxazepam Oxazepam Oxazepam may decrease the excretion rate of Mirabegron which could result in a higher serum level.
Flurazepam Flurazepam Flurazepam may decrease the excretion rate of Mirabegron which could result in a higher serum level.
Clorazepate Clorazepate Clorazepic acid may decrease the excretion rate of Mirabegron which could result in a higher serum level.
Lorazepam Lorazepam Lorazepam may decrease the excretion rate of Mirabegron which could result in a higher serum level.
Phenoxybenzamine Phenoxybenzamine The therapeutic efficacy of Mirabegron can be decreased when used in combination with Phenoxybenzamine.
Carmustine Carmustine Carmustine may decrease the excretion rate of Mirabegron which could result in a higher serum level.
Amantadine Amantadine The risk or severity of QTc prolongation can be increased when Amantadine is combined with Mirabegron.
Codeine Codeine The metabolism of Mirabegron can be decreased when combined with Codeine.
Bromocriptine Bromocriptine Mirabegron may increase the hypertensive and vasoconstricting activities of Bromocriptine.
Metaproterenol Metaproterenol The risk or severity of hypertension can be increased when Orciprenaline is combined with Mirabegron.
Tranylcypromine Tranylcypromine The metabolism of Mirabegron can be decreased when combined with Tranylcypromine.
Phenelzine Phenelzine The metabolism of Mirabegron can be decreased when combined with Phenelzine.
Ergoloid Mesylates Ergoloid Mesylates Ergoloid mesylate may increase the hypertensive and vasoconstricting activities of Mirabegron.
Tetracycline Tetracycline Tetracycline may decrease the excretion rate of Mirabegron which could result in a higher serum level.
Prochlorperazine Prochlorperazine The metabolism of Prochlorperazine can be decreased when combined with Mirabegron.
Thioridazine Thioridazine The metabolism of Mirabegron can be decreased when combined with Thioridazine.
Trifluoperazine Trifluoperazine The therapeutic efficacy of Mirabegron can be decreased when used in combination with Trifluoperazine.
Bleomycin Bleomycin Bleomycin may decrease the excretion rate of Mirabegron which could result in a higher serum level.
Sulfadiazine Sulfadiazine Sulfadiazine may decrease the excretion rate of Mirabegron which could result in a higher serum level.
Oxycodone Oxycodone The metabolism of Mirabegron can be decreased when combined with Oxycodone.
Methadone Methadone The metabolism of Mirabegron can be decreased when combined with Methadone.
Oxybutynin Oxybutynin The risk or severity of urinary retention can be increased when Oxybutynin is combined with Mirabegron.
Benztropine Benztropine The risk or severity of urinary retention can be increased when Benzatropine is combined with Mirabegron.
Maprotiline Maprotiline The risk or severity of urinary retention can be increased when Maprotiline is combined with Mirabegron.
Ibuprofen Ibuprofen Ibuprofen may decrease the excretion rate of Mirabegron which could result in a higher serum level.
Trihexyphenidyl Trihexyphenidyl The risk or severity of urinary retention can be increased when Trihexyphenidyl is combined with Mirabegron.
Orphenadrine Orphenadrine The risk or severity of urinary retention can be increased when Orphenadrine is combined with Mirabegron.
Perphenazine Perphenazine The metabolism of Mirabegron can be decreased when combined with Perphenazine.
Azathioprine Azathioprine Azathioprine may decrease the excretion rate of Mirabegron which could result in a higher serum level.
Fluphenazine Fluphenazine The metabolism of Mirabegron can be decreased when combined with Fluphenazine.
Phentermine Phentermine The risk or severity of hypertension can be increased when Phentermine is combined with Mirabegron.
Methylphenidate Methylphenidate Methylphenidate may decrease the excretion rate of Mirabegron which could result in a higher serum level.
Amoxapine Amoxapine The risk or severity of urinary retention can be increased when Amoxapine is combined with Mirabegron.
Sulfasalazine Sulfasalazine Sulfasalazine may decrease the excretion rate of Mirabegron which could result in a higher serum level.
Doxorubicin Doxorubicin The serum concentration of Doxorubicin can be increased when it is combined with Mirabegron.
Mechlorethamine Mechlorethamine Mechlorethamine may increase the neuromuscular blocking activities of Mirabegron.
Dactinomycin Dactinomycin The serum concentration of Mirabegron can be increased when it is combined with Dactinomycin.
Pyridostigmine Pyridostigmine Pyridostigmine may increase the neuromuscular blocking activities of Mirabegron.
Phenazopyridine Phenazopyridine Phenazopyridine may decrease the excretion rate of Mirabegron which could result in a higher serum level.
Carbamazepine Carbamazepine Carbamazepine may decrease the excretion rate of Mirabegron which could result in a higher serum level.
Methyldopa Methyldopa Methyldopa may decrease the excretion rate of Mirabegron which could result in a higher serum level.
Clonidine Clonidine The serum concentration of Clonidine can be increased when it is combined with Mirabegron.
Prazosin Prazosin The therapeutic efficacy of Prazosin can be decreased when used in combination with Mirabegron.
Hydralazine Hydralazine Hydralazine may decrease the excretion rate of Mirabegron which could result in a higher serum level.
Cimetidine Cimetidine The metabolism of Mirabegron can be decreased when combined with Cimetidine.
Gentamicin Injection Gentamicin Injection Gentamicin may decrease the excretion rate of Mirabegron which could result in a higher serum level.
Warfarin Warfarin Warfarin may decrease the excretion rate of Mirabegron which could result in a higher serum level.
Clonazepam Clonazepam Clonazepam may decrease the excretion rate of Mirabegron which could result in a higher serum level.
Loperamide Loperamide The metabolism of Mirabegron can be decreased when combined with Loperamide.
Promethazine Promethazine The risk or severity of urinary retention can be increased when Promethazine is combined with Mirabegron.
Meclofenamate Meclofenamate Meclofenamic acid may decrease the excretion rate of Mirabegron which could result in a higher serum level.
Nitrofurantoin Nitrofurantoin Nitrofurantoin may decrease the excretion rate of Mirabegron which could result in a higher serum level.
Digoxin Digoxin Mirabegron may decrease the excretion rate of Digoxin which could result in a higher serum level.
Loxapine Loxapine The serum concentration of Mirabegron can be increased when it is combined with Loxapine.
Chloroquine Chloroquine The metabolism of Mirabegron can be decreased when combined with Chloroquine.
Quinine Quinine The metabolism of Quinine can be decreased when combined with Mirabegron.
Ethosuximide Ethosuximide The risk or severity of QTc prolongation can be increased when Ethosuximide is combined with Mirabegron.
Triamterene Triamterene Triamterene may decrease the excretion rate of Mirabegron which could result in a higher serum level.
Chlorothiazide Chlorothiazide Chlorothiazide may increase the excretion rate of Mirabegron which could result in a lower serum level and potentially a reduction in efficacy.
Chlorthalidone Chlorthalidone Chlorthalidone may increase the excretion rate of Mirabegron which could result in a lower serum level and potentially a reduction in efficacy.
Metolazone Metolazone Metolazone may increase the excretion rate of Mirabegron which could result in a lower serum level and potentially a reduction in efficacy.
Isosorbide Isosorbide Isosorbide may increase the excretion rate of Mirabegron which could result in a lower serum level and potentially a reduction in efficacy.
Secobarbital Secobarbital Secobarbital may decrease the excretion rate of Mirabegron which could result in a higher serum level.
Desipramine Desipramine The risk or severity of urinary retention can be increased when Mirabegron is combined with Desipramine.
Amitriptyline Amitriptyline The risk or severity of urinary retention can be increased when Amitriptyline is combined with Mirabegron.
Imipramine Imipramine The risk or severity of urinary retention can be increased when Imipramine is combined with Mirabegron.
Probenecid Probenecid Probenecid may decrease the excretion rate of Mirabegron which could result in a higher serum level.
Quinidine Quinidine The risk or severity of urinary retention can be increased when Quinidine is combined with Mirabegron.
Procainamide Procainamide The serum concentration of Procainamide can be increased when it is combined with Mirabegron.
Isoniazid Isoniazid Isoniazid may decrease the excretion rate of Mirabegron which could result in a higher serum level.
Pyrazinamide Pyrazinamide Pyrazinamide may decrease the excretion rate of Mirabegron which could result in a higher serum level.
Disopyramide Disopyramide The risk or severity of urinary retention can be increased when Disopyramide is combined with Mirabegron.
Valproic Acid Valproic Acid The risk or severity of QTc prolongation can be increased when Mirabegron is combined with Valproic acid.
Tamoxifen Tamoxifen The serum concentration of Mirabegron can be increased when it is combined with Tamoxifen.
Butabarbital Butabarbital Butabarbital may decrease the excretion rate of Mirabegron which could result in a higher serum level.
Liothyronine Liothyronine Liothyronine may decrease the excretion rate of Mirabegron which could result in a higher serum level.
Methimazole Methimazole The metabolism of Mirabegron can be decreased when combined with Methimazole.
Chlorpropamide Chlorpropamide Chlorpropamide may decrease the excretion rate of Mirabegron which could result in a higher serum level.
Tolbutamide Tolbutamide Tolbutamide may decrease the excretion rate of Mirabegron which could result in a higher serum level.
Tolazamide Tolazamide Tolazamide may decrease the excretion rate of Mirabegron which could result in a higher serum level.
Dextromethorphan Dextromethorphan The metabolism of Mirabegron can be decreased when combined with Dextromethorphan.
Niacin Niacin The metabolism of Mirabegron can be decreased when combined with Niacin.
Baclofen Baclofen Baclofen may decrease the excretion rate of Mirabegron which could result in a higher serum level.
Doxylamine Doxylamine The risk or severity of urinary retention can be increased when Doxylamine is combined with Mirabegron.
Cyproheptadine Cyproheptadine The risk or severity of urinary retention can be increased when Cyproheptadine is combined with Mirabegron.
Clemastine Clemastine The risk or severity of QTc prolongation can be increased when Mirabegron is combined with Clemastine.
Chlorpheniramine Chlorpheniramine The metabolism of Chlorpheniramine can be decreased when combined with Mirabegron.
Brompheniramine Brompheniramine The risk or severity of QTc prolongation can be increased when Dexbrompheniramine is combined with Mirabegron.
Meclizine Meclizine The metabolism of Mirabegron can be decreased when combined with Meclizine.
Ethambutol Ethambutol Ethambutol may decrease the excretion rate of Mirabegron which could result in a higher serum level.
Methyclothiazide Methyclothiazide Methyclothiazide may increase the excretion rate of Mirabegron which could result in a lower serum level and potentially a reduction in efficacy.
Hydrochlorothiazide Hydrochlorothiazide Hydrochlorothiazide may decrease the excretion rate of Mirabegron which could result in a higher serum level.
Chlorzoxazone Chlorzoxazone The metabolism of Mirabegron can be decreased when combined with Chlorzoxazone.
Pyridoxine Pyridoxine Pyridoxine may decrease the excretion rate of Mirabegron which could result in a higher serum level.
Folic Acid Folic Acid Folic acid may decrease the excretion rate of Mirabegron which could result in a higher serum level.
Disulfiram Disulfiram The risk or severity of QTc prolongation can be increased when Disulfiram is combined with Mirabegron.
Propranolol (Cardiovascular) Propranolol (Cardiovascular) The metabolism of Mirabegron can be decreased when combined with Propranolol.
Minoxidil Minoxidil Mirabegron may decrease the antihypertensive activities of Minoxidil.
Pseudoephedrine Pseudoephedrine The risk or severity of hypertension can be increased when Pseudoephedrine is combined with Mirabegron.
Nortriptyline Nortriptyline The risk or severity of urinary retention can be increased when Nortriptyline is combined with Mirabegron.
Spironolactone Spironolactone The therapeutic efficacy of Mirabegron can be decreased when used in combination with Spironolactone.
Amphotericin B Injection Amphotericin B Injection Amphotericin B may decrease the excretion rate of Mirabegron which could result in a higher serum level.
Phytonadione Phytonadione Phylloquinone may decrease the excretion rate of Mirabegron which could result in a higher serum level.
Amikacin Injection Amikacin Injection Amikacin may decrease the excretion rate of Mirabegron which could result in a higher serum level.
Nadolol Nadolol The metabolism of Nadolol can be decreased when combined with Mirabegron.
Allopurinol Allopurinol Allopurinol may decrease the excretion rate of Mirabegron which could result in a higher serum level.
Oxytocin Injection Oxytocin Injection The risk or severity of QTc prolongation can be increased when Oxytocin is combined with Mirabegron.
Clomiphene Clomiphene The serum concentration of Mirabegron can be increased when it is combined with Clomifene.
Flavoxate Flavoxate The risk or severity of urinary retention can be increased when Flavoxate is combined with Mirabegron.
Papaverine Papaverine The risk or severity of QTc prolongation can be increased when Mirabegron is combined with Papaverine.
Fluorouracil Injection Fluorouracil Injection The risk or severity of QTc prolongation can be increased when Mirabegron is combined with Fluorouracil.
Colchicine Colchicine The serum concentration of Colchicine can be increased when it is combined with Mirabegron.
Cefaclor Cefaclor Cefaclor may decrease the excretion rate of Mirabegron which could result in a higher serum level.
Cefadroxil Cefadroxil Cefadroxil may decrease the excretion rate of Mirabegron which could result in a higher serum level.
Cefazolin Injection Cefazolin Injection Cefazolin may decrease the excretion rate of Mirabegron which could result in a higher serum level.
Cephalexin Cephalexin Cephalexin may decrease the excretion rate of Mirabegron which could result in a higher serum level.
Cefoxitin Injection Cefoxitin Injection Cefoxitin may decrease the excretion rate of Mirabegron which could result in a higher serum level.
Dacarbazine Dacarbazine Dacarbazine may decrease the excretion rate of Mirabegron which could result in a higher serum level.
Acetazolamide Acetazolamide Acetazolamide may increase the excretion rate of Mirabegron which could result in a lower serum level and potentially a reduction in efficacy.
Cefotaxime Injection Cefotaxime Injection Cefotaxime may decrease the excretion rate of Mirabegron which could result in a higher serum level.
Calcitonin Salmon Injection Calcitonin Salmon Injection Salmon calcitonin may decrease the excretion rate of Mirabegron which could result in a higher serum level.
Ketoconazole Ketoconazole The serum concentration of Mirabegron can be increased when it is combined with Ketoconazole.
Pyrantel Pyrantel Mirabegron may decrease the excretion rate of Pyrantel which could result in a higher serum level.
Thiotepa Injection Thiotepa Injection Thiotepa may increase the neuromuscular blocking activities of Mirabegron.
Vincristine Injection Vincristine Injection The excretion of Vincristine can be decreased when combined with Mirabegron.
Captopril Captopril Mirabegron may decrease the antihypertensive activities of Captopril.
Isoxsuprine Isoxsuprine The risk or severity of hypertension can be increased when Mirabegron is combined with Isoxsuprine.
Vinblastine Vinblastine The serum concentration of Mirabegron can be increased when it is combined with Vinblastine.
Ethacrynic Acid Ethacrynic Acid Etacrynic acid may decrease the excretion rate of Mirabegron which could result in a higher serum level.
Colistimethate Injection Colistimethate Injection Colistimethate may decrease the excretion rate of Mirabegron which could result in a higher serum level.
Metoprolol Metoprolol Mirabegron may decrease the antihypertensive activities of Metoprolol.
Hydroxyzine Hydroxyzine The risk or severity of QTc prolongation can be increased when Hydroxyzine is combined with Mirabegron.
Thiothixene Thiothixene The risk or severity of QTc prolongation can be increased when Thiothixene is combined with Mirabegron.
Aspirin Aspirin Acetylsalicylic acid may decrease the excretion rate of Mirabegron which could result in a higher serum level.
Salsalate Salsalate Salsalate may decrease the excretion rate of Mirabegron which could result in a higher serum level.
Alprazolam Alprazolam Alprazolam may decrease the excretion rate of Mirabegron which could result in a higher serum level.
Temazepam Temazepam Temazepam may decrease the excretion rate of Mirabegron which could result in a higher serum level.
Triazolam Triazolam Triazolam may decrease the excretion rate of Mirabegron which could result in a higher serum level.
Dicyclomine Dicyclomine The risk or severity of urinary retention can be increased when Dicyclomine is combined with Mirabegron.
Hyoscyamine Hyoscyamine The risk or severity of urinary retention can be increased when Hyoscyamine is combined with Mirabegron.
Propantheline Propantheline The risk or severity of urinary retention can be increased when Propantheline is combined with Mirabegron.
Trimethoprim Trimethoprim Trimethoprim may decrease the excretion rate of Mirabegron which could result in a higher serum level.
Diltiazem Diltiazem The metabolism of Mirabegron can be decreased when combined with Diltiazem.
Nifedipine Nifedipine The metabolism of Mirabegron can be decreased when combined with Nifedipine.
Timolol Timolol The metabolism of Timolol can be decreased when combined with Mirabegron.
Verapamil Verapamil The serum concentration of Mirabegron can be increased when it is combined with Verapamil.
Atenolol Atenolol The metabolism of Mirabegron can be decreased when combined with Atenolol.
Pindolol Pindolol The metabolism of Mirabegron can be decreased when combined with Pindolol.
Cisplatin Injection Cisplatin Injection Mirabegron may decrease the excretion rate of Cisplatin which could result in a higher serum level.
Diflunisal Diflunisal Diflunisal may decrease the excretion rate of Mirabegron which could result in a higher serum level.
Piroxicam Piroxicam Piroxicam may decrease the excretion rate of Mirabegron which could result in a higher serum level.
Bumetanide Bumetanide Bumetanide may increase the excretion rate of Mirabegron which could result in a lower serum level and potentially a reduction in efficacy.
Etoposide Etoposide The serum concentration of Mirabegron can be increased when it is combined with Etoposide.
Glipizide Glipizide Glipizide may decrease the excretion rate of Mirabegron which could result in a higher serum level.
Indapamide Indapamide Indapamide may increase the excretion rate of Mirabegron which could result in a lower serum level and potentially a reduction in efficacy.
Amoxicillin Amoxicillin Amoxicillin may decrease the excretion rate of Mirabegron which could result in a higher serum level.
Oxacillin Injection Oxacillin Injection Oxacillin may decrease the excretion rate of Mirabegron which could result in a higher serum level.
Pentoxifylline Pentoxifylline Pentoxifylline may decrease the excretion rate of Mirabegron which could result in a higher serum level.
Pentamidine Injection Pentamidine Injection The metabolism of Mirabegron can be decreased when combined with Pentamidine.
Ceftriaxone Injection Ceftriaxone Injection Ceftriaxone may decrease the excretion rate of Mirabegron which could result in a higher serum level.
Labetalol Labetalol The metabolism of Mirabegron can be decreased when combined with Labetalol.
Auranofin Auranofin Auranofin may decrease the excretion rate of Mirabegron which could result in a higher serum level.
Leuprolide Injection Leuprolide Injection The risk or severity of QTc prolongation can be increased when Mirabegron is combined with Leuprolide.
Gemfibrozil Gemfibrozil Gemfibrozil may decrease the excretion rate of Mirabegron which could result in a higher serum level.
Guanabenz Guanabenz The risk or severity of hypertension can be increased when Guanabenz is combined with Mirabegron.
Dipivefrin Ophthalmic Dipivefrin Ophthalmic Adefovir dipivoxil may decrease the excretion rate of Mirabegron which could result in a higher serum level.
Ceftazidime Injection Ceftazidime Injection Ceftazidime may decrease the excretion rate of Mirabegron which could result in a higher serum level.
Ketoprofen Ketoprofen Ketoprofen may decrease the excretion rate of Mirabegron which could result in a higher serum level.
Cefotetan Injection Cefotetan Injection Cefotetan may decrease the excretion rate of Mirabegron which could result in a higher serum level.
Pimozide Pimozide The serum concentration of Pimozide can be increased when it is combined with Mirabegron.
Enalapril Enalapril Mirabegron may decrease the antihypertensive activities of Enalapril.
Flurbiprofen Flurbiprofen Flurbiprofen may decrease the excretion rate of Mirabegron which could result in a higher serum level.
Amiodarone Amiodarone The serum concentration of Mirabegron can be increased when it is combined with Amiodarone.
Aztreonam Injection Aztreonam Injection Aztreonam may decrease the excretion rate of Mirabegron which could result in a higher serum level.
Buspirone Buspirone The metabolism of Mirabegron can be decreased when combined with Buspirone.
Lovastatin Lovastatin The metabolism of Mirabegron can be decreased when combined with Lovastatin.
Ciprofloxacin Ciprofloxacin The risk or severity of QTc prolongation can be increased when Mirabegron is combined with Ciprofloxacin.
Mesalamine Mesalamine Mesalazine may decrease the excretion rate of Mirabegron which could result in a higher serum level.
Diclofenac Diclofenac Diclofenac may decrease the excretion rate of Mirabegron which could result in a higher serum level.
Fluoxetine Fluoxetine The serum concentration of Mirabegron can be increased when it is combined with Fluoxetine.
Nimodipine Nimodipine The risk or severity of QTc prolongation can be increased when Mirabegron is combined with Nimodipine.
Clozapine Clozapine The risk or severity of urinary retention can be increased when Clozapine is combined with Mirabegron.
Estazolam Estazolam Estazolam may decrease the excretion rate of Mirabegron which could result in a higher serum level.
Idarubicin Idarubicin The metabolism of Mirabegron can be decreased when combined with Idarubicin.
Ofloxacin Ofloxacin The risk or severity of QTc prolongation can be increased when Mirabegron is combined with Ofloxacin.
Didanosine Didanosine Didanosine may decrease the excretion rate of Mirabegron which could result in a higher serum level.
Pentostatin Injection Pentostatin Injection Pentostatin may decrease the excretion rate of Mirabegron which could result in a higher serum level.
Clarithromycin Clarithromycin The serum concentration of Mirabegron can be increased when it is combined with Clarithromycin.
Benazepril Benazepril Mirabegron may decrease the antihypertensive activities of Benazepril.
Etodolac Etodolac Etodolac may decrease the excretion rate of Mirabegron which could result in a higher serum level.
Felodipine Felodipine The metabolism of Felodipine can be decreased when combined with Mirabegron.
Fosinopril Fosinopril Fosinopril may decrease the excretion rate of Mirabegron which could result in a higher serum level.
Nabumetone Nabumetone Nabumetone may decrease the excretion rate of Mirabegron which could result in a higher serum level.
Pravastatin Pravastatin The serum concentration of Mirabegron can be increased when it is combined with Pravastatin.
Quinapril Quinapril Mirabegron may decrease the antihypertensive activities of Quinapril.
Ramipril Ramipril Mirabegron may decrease the antihypertensive activities of Ramipril.
Simvastatin Simvastatin The metabolism of Mirabegron can be decreased when combined with Simvastatin.
Amlodipine Amlodipine Mirabegron may decrease the antihypertensive activities of Amlodipine.
Itraconazole Itraconazole The serum concentration of Mirabegron can be increased when it is combined with Itraconazole.
Lisinopril Lisinopril Lisinopril may decrease the excretion rate of Mirabegron which could result in a higher serum level.
Oxaprozin Oxaprozin Oxaprozin may decrease the excretion rate of Mirabegron which could result in a higher serum level.
Sotalol Sotalol The serum concentration of Sotalol can be increased when it is combined with Mirabegron.
Bisoprolol Bisoprolol The therapeutic efficacy of Mirabegron can be decreased when used in combination with Bisoprolol.
Zolpidem Zolpidem The metabolism of Zolpidem can be decreased when combined with Mirabegron.
Doxazosin Doxazosin The metabolism of Mirabegron can be decreased when combined with Doxazosin.
Terazosin Terazosin The therapeutic efficacy of Terazosin can be decreased when used in combination with Mirabegron.
Isradipine Isradipine The risk or severity of QTc prolongation can be increased when Mirabegron is combined with Isradipine.
Omeprazole Omeprazole The metabolism of Mirabegron can be decreased when combined with Omeprazole.
Cisapride Cisapride The metabolism of Cisapride can be decreased when combined with Mirabegron.
Fluvastatin Fluvastatin The metabolism of Mirabegron can be decreased when combined with Fluvastatin.
Venlafaxine Venlafaxine The metabolism of Mirabegron can be decreased when combined with Venlafaxine.
Nizatidine Nizatidine Nizatidine may increase the neuromuscular blocking activities of Mirabegron.
Fluvoxamine Fluvoxamine The metabolism of Mirabegron can be decreased when combined with Fluvoxamine.
Nefazodone Nefazodone The metabolism of Mirabegron can be decreased when combined with Nefazodone.
Lamotrigine Lamotrigine The risk or severity of urinary retention can be increased when Lamotrigine is combined with Mirabegron.
Losartan Losartan The risk or severity of QTc prolongation can be increased when Mirabegron is combined with Losartan.
Valacyclovir Valacyclovir Valaciclovir may decrease the excretion rate of Mirabegron which could result in a higher serum level.
Tramadol Tramadol The risk or severity of urinary retention can be increased when Tramadol is combined with Mirabegron.
Vinorelbine Injection Vinorelbine Injection The metabolism of Mirabegron can be decreased when combined with Vinorelbine.
Carboplatin Injection Carboplatin Injection Carboplatin may decrease the excretion rate of Mirabegron which could result in a higher serum level.
Moexipril Moexipril The risk or severity of QTc prolongation can be increased when Moexipril is combined with Mirabegron.
Lansoprazole Lansoprazole The metabolism of Mirabegron can be decreased when combined with Lansoprazole.
Ifosfamide Injection Ifosfamide Injection Ifosfamide may decrease the excretion rate of Mirabegron which could result in a higher serum level.
Nicardipine Nicardipine The risk or severity of urinary retention can be increased when Nicardipine is combined with Mirabegron.
Bupropion Bupropion The metabolism of Mirabegron can be decreased when combined with Bupropion.
Ticlopidine Ticlopidine The metabolism of Mirabegron can be decreased when combined with Ticlopidine.
Saquinavir Saquinavir The serum concentration of Saquinavir can be increased when it is combined with Mirabegron.
Metformin Metformin Metformin may decrease the excretion rate of Mirabegron which could result in a higher serum level.
Nisoldipine Nisoldipine Mirabegron may decrease the excretion rate of Nisoldipine which could result in a higher serum level.
Lamivudine Lamivudine Lamivudine may decrease the excretion rate of Mirabegron which could result in a higher serum level.
Acarbose Acarbose Acarbose may decrease the excretion rate of Mirabegron which could result in a higher serum level.
Gemcitabine Injection Gemcitabine Injection The serum concentration of Mirabegron can be increased when it is combined with Gemcitabine.
Ritonavir Ritonavir The serum concentration of Mirabegron can be increased when it is combined with Ritonavir.
Cidofovir Injection Cidofovir Injection Cidofovir may decrease the excretion rate of Mirabegron which could result in a higher serum level.
Meropenem Injection Meropenem Injection Meropenem may decrease the excretion rate of Mirabegron which could result in a higher serum level.
Clomipramine Clomipramine The serum concentration of Mirabegron can be increased when it is combined with Clomipramine.
Fosfomycin Fosfomycin Fosfomycin may decrease the excretion rate of Mirabegron which could result in a higher serum level.
Mirtazapine Mirtazapine The metabolism of Mirabegron can be decreased when combined with Mirtazapine.
Trandolapril Trandolapril Mirabegron may decrease the antihypertensive activities of Trandolapril.
Topiramate Topiramate Topiramate may decrease the excretion rate of Mirabegron which could result in a higher serum level.
Valsartan Valsartan Mirabegron may decrease the antihypertensive activities of Valsartan.
Pramipexole Pramipexole Pramipexole may decrease the excretion rate of Mirabegron which could result in a higher serum level.
Donepezil Donepezil The metabolism of Donepezil can be decreased when combined with Mirabegron.
Nelfinavir Nelfinavir The metabolism of Mirabegron can be decreased when combined with Nelfinavir.
Fexofenadine Fexofenadine The serum concentration of Mirabegron can be increased when it is combined with Fexofenadine.
Azithromycin Azithromycin The risk or severity of QTc prolongation can be increased when Mirabegron is combined with Azithromycin.
Carvedilol Carvedilol The metabolism of Mirabegron can be decreased when combined with Carvedilol.
Nilutamide Nilutamide Nilutamide may decrease the excretion rate of Mirabegron which could result in a higher serum level.
Flutamide Flutamide Flutamide may decrease the excretion rate of Mirabegron which could result in a higher serum level.
Selegiline Selegiline The metabolism of Mirabegron can be decreased when combined with Selegiline.
Bicalutamide Bicalutamide The metabolism of Mirabegron can be decreased when combined with Bicalutamide.
Sertraline Sertraline The metabolism of Mirabegron can be decreased when combined with Sertraline.
Propafenone Propafenone The metabolism of Propafenone can be decreased when combined with Mirabegron.
Irbesartan Irbesartan Mirabegron may decrease the antihypertensive activities of Irbesartan.
Tamsulosin Tamsulosin The metabolism of Mirabegron can be decreased when combined with Tamsulosin.
Finasteride Finasteride The risk or severity of hypertension can be increased when Finasteride is combined with Mirabegron.
Quetiapine Quetiapine The risk or severity of urinary retention can be increased when Quetiapine is combined with Mirabegron.
Cefepime Injection Cefepime Injection Cefepime may decrease the excretion rate of Mirabegron which could result in a higher serum level.
Cefprozil Cefprozil Cefprozil may decrease the excretion rate of Mirabegron which could result in a higher serum level.
Cefpodoxime Cefpodoxime Cefpodoxime may decrease the excretion rate of Mirabegron which could result in a higher serum level.
Cetirizine Cetirizine The risk or severity of QTc prolongation can be increased when Cetirizine is combined with Mirabegron.
Paroxetine Paroxetine The risk or severity of urinary retention can be increased when Paroxetine is combined with Mirabegron.
Tolcapone Tolcapone Tolcapone may decrease the excretion rate of Mirabegron which could result in a higher serum level.
Citalopram Citalopram The metabolism of Citalopram can be decreased when combined with Mirabegron.
Capecitabine Capecitabine Capecitabine may decrease the excretion rate of Mirabegron which could result in a higher serum level.
Efavirenz Efavirenz The risk or severity of QTc prolongation can be increased when Mirabegron is combined with Efavirenz.
Abacavir Abacavir Abacavir may decrease the excretion rate of Mirabegron which could result in a higher serum level.
Sildenafil Sildenafil The metabolism of Mirabegron can be decreased when combined with Sildenafil.
Celecoxib Celecoxib The metabolism of Mirabegron can be decreased when combined with Celecoxib.
Rosiglitazone Rosiglitazone The metabolism of Mirabegron can be decreased when combined with Rosiglitazone.
Tolterodine Tolterodine The risk or severity of urinary retention can be increased when Tolterodine is combined with Mirabegron.
Oseltamivir Oseltamivir Oseltamivir may decrease the excretion rate of Mirabegron which could result in a higher serum level.
Balsalazide Balsalazide Balsalazide may decrease the excretion rate of Mirabegron which could result in a higher serum level.
Nateglinide Nateglinide The metabolism of Mirabegron can be decreased when combined with Nateglinide.
Galantamine Galantamine The metabolism of Mirabegron can be decreased when combined with Galantamine.
Rabeprazole Rabeprazole Rabeprazole may decrease the excretion rate of Mirabegron which could result in a higher serum level.
Terbinafine Terbinafine The metabolism of Mirabegron can be decreased when combined with Terbinafine.

Content provided by: AHFS® Patient Medication Information™. © Copyright, 2021. The American Society of Health-System Pharmacists